-
Senaste pressmeddelande
-
Finansiella rapporter
-
Aktieinformation
Handelsinformation
Glycorex-aktien är noterad och handlas på börsen Nordic Growth Market (NGM).
Glycorex Transplantation AB noterades på NGM Equity Stockholm 2001.
Symbol: GTAB B
ISIN-kod: SE0000524530
World-leader in
ABO-incompatible technologies
Glycosorb®-ABO enables blood group incompatible transplants. Glycosorb®-ABO reduce anti-A/B antibodies in human plasma through A/B antigen specific binding. Glycosorb®-ABO has been used clinically since 2001. To date, transplant centres on four continents have treated more than 3,000 adult and paediatric patients.
Transplantation reduces health-care costs. In Sweden it is estimated that every successful kidney transplant saves a total of approximately 5 million Swedish kronor over a ten-year period compared with giving dialysis.
The Glycorex Group possesses unique know-how and proficiency in the fields of biologically active carbohydrate substances and extracorporeal blood treatment. This provides the foundation for the development work that the subsidiaries Glycoprobe and Glycorex UBP are doing in the fields of autoimmune diseases and universal blood plasma respectively.